Janssen Pharmaceutical Inc.
1125 Trenton-Harbourton Road
Titusville
New Jersey
08560
United States
Tel: 609-730-2000
295 articles with Janssen Pharmaceutical Inc.
-
The approval is based on the Phase III UNIFI study that showed that after eight weeks of taking a single intravenous dose of Stelara, patients saw “clinical remission in a significantly greater proportion of UC patients.”
-
Clinical Catch-Up: October 14-18
10/21/2019
Last week was busy for clinical trial news. Here’s a look. -
Janssen Pharmaceutical of Johnson & Johnson released new long-term data from the open-label period of its Phase III VOYAGE 1 clinical trial.
-
Janssen Presents New Four-Year TREMFYA® (guselkumab) Data Demonstrating Maintained Rates of Skin Clearance in Adult Patients with Moderate to Severe Plaque Psoriasis
10/17/2019
At 204 weeks, patients receiving TREMFYA® in a clinical study continue to show maintained PASI 90 and IGA 0/1 responses
-
The U.S. Food and Drug Administration approved Janssen Pharmaceutical's Xarelto for the prevention of venous thromboembolism, or blood clots, in acutely sick patients in hospitals who are at risk for blood clots but who are not at high risk of bleeding.
-
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Niraparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer
10/3/2019
Niraparib, an orally-administered PARP inhibitor, is currently being investigated for the treatment of patients with metastatic castration-resistant prostate cancer and BRCA1/2 DNA repair gene defects
-
Janssen Submits Supplemental New Drug Application to U.S. FDA for SPRAVATO® (esketamine) CIII Nasal Spray for the Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent
10/2/2019
If approved, SPRAVATO® would be the first treatment for this severely ill population(1) who historically have been excluded from antidepressant clinical trials
-
Janssen's Invokana Becomes First Drug Approved in 20 Years to Slow Diabetic Kidney Disease
10/1/2019
Janssen’s Invokana snagged another regulatory approval to reduce the risk of end-stage kidney disease, cardiovascular death and worsening of kidney function in adults with type 2 diabetes and diabetic kidney disease. -
FDA Approves New Drug to Treat Diabetes-Related Kidney Disease
9/30/2019
The National Kidney Foundation Statement about INVOKANA® (Canagliflozin)
-
U.S. FDA Approves INVOKANA® (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes (T2D) and DKD
9/30/2019
INVOKANA® is the only diabetes medicine indicated to slow the progression of diabetic nephropathy (also known as DKD) and reduce the risk of hospitalization for heart failure in patients with T2D and DKD
-
Insilico and Janssen take another step towards predictive biomanufacturing: Digital Twins allow for accelerated timelines in cell line development for biologics production
9/27/2019
Insilico Biotechnology AG and the Janssen Pharmaceutical Companies of Johnson & Johnson announced an agreement to apply Insilico's predictive Digital Twins for the early selection of high-performing cells to further boost efficiency and throughput of their cell line development workflow.
-
Updated Results of the SPARTAN Study Show 25 Percent Reduction in the Risk of Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) Treated with ERLEADA® (apalutamide)
9/27/2019
Results from the second interim analysis of the Phase 3 SPARTAN study featured in an oral presentation at ESMO 2019 and simultaneously published in Annals of Oncology
-
Treatment with Erleada plus androgen deprivation therapy resulted in a 25% reduction in the risk of death compared to placebo in prostate cancer patients.
-
The FDA’s latest approval for Darzalex is based on results from the Phase III CASSIOPEIA trial that showed the addition of Darzalex to VTd before and after ASCT resulted in deeper responses in patients with the blood cancer.
-
Janssen Announces U.S. FDA Approval of DARZALEX® (daratumumab) Combination Regimen for Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma
9/26/2019
Approval represents first and only FDA-approved biologic indicated for newly diagnosed patients who are eligible for a stem cell transplant
-
FDA Approves Prostate Cancer Drug ERLEADA for New Indication
9/25/2019
U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patientsbwith Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
-
Janssen to Highlight Depth of Solid Tumour Portfolio with Multiple Data Presentations at ESMO 2019
9/25/2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced multiple data presentations from its solid tumour portfolio, including key prostate cancer data, will be featured at the European Society for Medical Oncology 2019 Annual Congress, taking place 27th September to 1st October in Barcelona, Spain.
-
Clinical Catch-Up: September 16-20
9/23/2019
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories. -
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patientsbwith Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
9/19/2019
Phase 3 TITAN is the first registrational study to achieve statistical significance in dual primary endpoints of overall survival and radiographic progression-free survival in patients with mCSPC regardless of extent of disease